Oxazole-bridged combretastatin A analogues with improved anticancer properties

ChemMedChem

Volumn 5, Issue 3, 2010, Pages 420-427

  Biersack, Bernhard ^a   Effenberger, Katharina ^a   Schobert, Rainer ^a   Ocker, Matthias ^b  

^a UNIVERSITY OF BAYREUTH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Antitumor agents; Combretastatin A; Oxazoles; Thioanisole; Tubulin

Indexed keywords

5 (2'' HYDROXY 4'' METHOXY 3'',6'' DIOXOCYCLOHEXA 1'',4'' DIENYL) 4 (3',4',5' TRIMETHOXYPHENYL)OXAZOLE; 5 (2'',3'' DIHYDROXY 4'' METHOXYPHENYL) 4 (3',4',5' TRIMETHOXYPHENYL); 5 [4' (METHYLSULFANYL)PHENYL] 4 (3',4',5' TRIMETHOXYPHENYL)OXAZOLE; COMBRETASTATIN A4; GUAIACOL; OXAZOLE DERIVATIVE; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MELANOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOSIS INHIBITION; PRIORITY JOURNAL; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBRETUM; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HL-60 CELLS; HT29 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OXAZOLES; REACTIVE OXYGEN SPECIES; STILBENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77249107910     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900477     Document Type: Article

References (20)

1. R. B. Pedley, S. A. Hill, G. M. Boxer, A. A. Flynn, R. Boden, R. Watson, J. Dearling, D. J. Chaplin, R. H. Begent, Cancer Res. 2001, 61, 4716-4722.
2. www.oxigene.com (last accessed: January 7, 2010).
3. a) S. Aprile, E. Del Grosso, G. C. Tron, G. Grosa, Drug Metab. Dispos. 2007, 35, 2252-2261;
4. b) G. C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca, A. Genazzani, J. Med. Chem. 2006, 49, 3033-3044.
5. L. Vincent, P. Kermani, L. M. Young, J. Cheng, F. Zhang, J. Clin. Invest. 2005, 115, 2992-3006.
6. C. Kanthou, G. M. Tozer, Blood 2002, 99, 2060-2069.
7. L. Wang, K. W. Woods, Q. Li, K. J. Barr, R. W. McCroskey, S. M. Hannick, L. Gherke, R. B. Credo, Y.-H. Hui, K. Marsh, R. Warner, J. Y. Lee, N. Zielinski-Mozng, D. Frost, S. H. Rosenberg, H. L. Sham, J. Med. Chem. 2002, 45, 1697-1711.
8. a) J. W. Lippert III, Bioorg. Med. Chem. 2007, 15, 605-615;
9. b) S. E. Holwell, P. A. Cooper, M. J. Thompson, G. R. Pettit, L. W. Lippert III, S. W. Martin, M. C. Bibby, Anticancer Res. 2002, 22, 3933-3940.
10. R. Schobert, B. Biersack, A. Dietrich, S. Knauer, M. Zoldakova, A. Frühauf, T. Müller, J. Med. Chem. 2009, 52, 241-246.
11. L. K. Folkes, M. Christlieb, E. Madej, M. R. L. Stratford, P. Wardman, Chem. Res. Toxicol. 2007, 20, 1885-1894.
12. L. Kaisalo, A. Latvala, T. Hase, Synth. Commun. 1986, 16, 645-648.
13. U. N. Das, M. E. Begin, G. Ells, Y. S. Huang, D. F. Hossobin, Biochem. Biophys. Res. Commun. 1987, 145, 15-24.
14. G. A. W. Rook, J. Steele, S. Umar, H. M. Dockrell, J. Immunol. Methods 1985, 82, 161-167.
15. S. Desagher, A. Osen-Sand, A. Nicholas, R. Eskes, S. Montessuit, J. Cell Biol. 1999, 144, 891-901.
16. a) M. Cushman, D. Nagarathnam, D. Gopal, H.-M. He, C. M. Lin, E. Hamel, J. Med. Chem. 1992, 35, 2293-2306;
17. b) H. Nakamura, H. Kuroda, H. Saito, R. Suzuki, T. Yamori, K. Maruyama, T. Haga, ChemMedChem 2006, 1, 729-740.
18. M. Ocker, R. Schneider-Stock, Int. J. Biochem. Cell Biol. 2007, 39, 1367-1374.
19. S. Jabari, M. Meissnitzer, K. Quint, S. Gahr, T. Wissniowski, E. G. Hahn, D. Neureiter, M. Ocker, Int. J. Oncol. 2009, 35, 69-80.
20. P. Di Fazio, R. Schneider-Stock, D. Neureiter, K. Okamoto, T. Wissniowski, S. Gahr, K. Quint, M. Meissnitzer, B. Alinger, R. Montalbano, G. Sass, B. Hohenstein, E. G. Hahn, M. Ocker, Cell. Oncol. 2010, in press.